Next Day Disclosure Return
Filed with HKEX · Stock code 1541 · · 6 pages · English
ImmuneOnco Biopharmaceuticals (Shanghai) Inc on 6ix
Earlier from ImmuneOnco Biopharmaceuticals (Shanghai)
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September, 2026
- Voluntary announcement - completion of capital Increase of a subsidiary
- 2026 Interim Report
- ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
- Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Later from ImmuneOnco Biopharmaceuticals (Shanghai)
All ImmuneOnco Biopharmaceuticals (Shanghai) news releasesFollow ImmuneOnco Biopharmaceuticals (Shanghai) into a list and get an email when it puts out news.
Follow ImmuneOnco Biopharmaceuticals (Shanghai)